MonTa Biosciences is a Clinical Stage Biotech Company focused on evaluating our lead candidate MBS8 in clinical trials to provide better treatment for patients in need. We have treated more then 30 patients with MBS8 in phase I units in Denmark, Belgium and Spain and seen a dose-dependent induction of biomarkers in patients which demonstrate a clear target engagement

MBS8 is a novel micelle formulation with several unique selling points:

  • Novel Mode of Action for recruitment of antitumor immune cells to the tumor tissue leading to tumor cell killing within hours
  • Immune stimulating micelle formulation engineered to reduce systemic cytokine production with a favorable safety profile
  • Administered using the intravenous route which is a major advantage for doctors and patients
  • Show a remarkable ability to stimulate neutrophil and CD8 T-cell mediated tumor cell killing which has shown important for patient prognosis and survival
  • MBS8 is a micellar formulation of a small molecule TLR7 NCE agonist
  • MBS8 show superior anti-tumor activity in monotherapy compared to many clinically approved therapies
  • Synergy with Immune Checkpoint Inhibitors, radiotherapy and chemotherapy with complete remission in preclinical models


Meet us in San Diego for SITC November 3-5, 2023

MonTa Biosciences will be joining the Society for Immunotherapy and Cancer Therapy (SITC) in San [...]

Read more
MonTa Biosciences treat the first patients with the highest dose of MBS8 ever

In the last week of September 2023 we dosed patient number 31 and 32 with [...]

Read more
Meet us at BIO International in Boston June 5-8 to discuss clinical development of MBS8

MonTas CEO; Simon S Jensen, PhD, will be joining the biggest partnership conference within Life [...]

Read more
New clinical site for MonTas phase I clinical trial in Madrid

We are happy to announce opening of a new clinical site for MonTas phase I [...]

Read more